Back to search
FDAFDA · Food and drugs·Recall number D-0658-2023

Cardioplegia Solution, Induction 4:1, High Potassium, 60 mEq K, packaged in 830 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., Lehigh Valley, 6580 Snowdrift Road, Allentown, PA 18106, NDC 71285-0100-1.

Published May 31, 2023 · Recall initiated: April 28, 2023

Summary

FDA records drug Class II recall D-0658-2023, published May 31, 2023 and initiated April 28, 2023. Recalling firm: Central Admixture Pharmacy Services, Inc.; Status: Terminated; Reported quantity: 267 bags; Lot: Lot # 37-894304, Exp 04/29/2023; 37-894946, Exp 05/01/2023; 37-896482, Exp 05/07/2023; 37-897933, Exp 05/13/2023; 37-900461, Exp 05/22/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Central Admixture Pharmacy Services, Inc.
Distributor
Nationwide in the USA.
Lot
Lot # 37-894304, Exp 04/29/2023; 37-894946, Exp 05/01/2023; 37-896482, Exp 05/07/2023; 37-897933, Exp 05/13/2023; 37-900461, Exp 05/22/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Cardioplegia Solution, Induction 4:1, High Potassium, 60 mEq K, packaged in 830 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., Lehigh Valley, 6580 Snowdrift Road, Allentown, PA 18106, NDC 71285-0100-1. recalled?

Yes. FDA published recall D-0658-2023 on May 31, 2023. Reported hazard: Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail